Park Avenue Securities LLC Invests $340,000 in Repligen Corporation $RGEN

Park Avenue Securities LLC acquired a new position in Repligen Corporation (NASDAQ:RGEN) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 2,736 shares of the biotechnology company’s stock, valued at approximately $340,000.

A number of other institutional investors and hedge funds have also modified their holdings of RGEN. Price T Rowe Associates Inc. MD raised its stake in Repligen by 6.0% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 7,566,093 shares of the biotechnology company’s stock valued at $962,711,000 after purchasing an additional 430,039 shares during the last quarter. Nuveen LLC acquired a new position in Repligen during the 1st quarter valued at $35,536,000. Artemis Investment Management LLP raised its stake in Repligen by 110.1% during the 1st quarter. Artemis Investment Management LLP now owns 323,229 shares of the biotechnology company’s stock valued at $41,128,000 after purchasing an additional 169,397 shares during the last quarter. GAMMA Investing LLC raised its stake in Repligen by 17,721.1% during the 1st quarter. GAMMA Investing LLC now owns 121,896 shares of the biotechnology company’s stock valued at $15,510,000 after purchasing an additional 121,212 shares during the last quarter. Finally, T. Rowe Price Investment Management Inc. raised its stake in Repligen by 64.0% during the 1st quarter. T. Rowe Price Investment Management Inc. now owns 260,848 shares of the biotechnology company’s stock valued at $33,191,000 after purchasing an additional 101,791 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, Director Martin D. Madaus acquired 1,800 shares of the firm’s stock in a transaction on Friday, August 8th. The shares were purchased at an average price of $112.13 per share, with a total value of $201,834.00. Following the acquisition, the director directly owned 1,800 shares in the company, valued at $201,834. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link. 1.20% of the stock is currently owned by corporate insiders.

Repligen Stock Up 7.7%

RGEN opened at $133.67 on Wednesday. The firm’s 50-day simple moving average is $120.80 and its 200-day simple moving average is $125.40. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.32 and a current ratio of 8.59. Repligen Corporation has a twelve month low of $102.96 and a twelve month high of $182.52. The firm has a market cap of $7.52 billion, a price-to-earnings ratio of -534.66, a PEG ratio of 2.29 and a beta of 1.07.

Repligen (NASDAQ:RGEN) last posted its earnings results on Tuesday, July 29th. The biotechnology company reported $0.37 earnings per share for the quarter, missing the consensus estimate of $0.40 by ($0.03). Repligen had a positive return on equity of 4.61% and a negative net margin of 2.05%.The firm had revenue of $182.37 million during the quarter, compared to the consensus estimate of $174.62 million. During the same period in the previous year, the company posted $0.40 EPS. The firm’s revenue for the quarter was up 14.8% compared to the same quarter last year. Repligen has set its FY 2025 guidance at 1.650-1.720 EPS. Equities research analysts anticipate that Repligen Corporation will post 1.72 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on RGEN shares. Wells Fargo & Company cut their target price on shares of Repligen from $180.00 to $175.00 and set an “overweight” rating for the company in a research note on Wednesday, July 30th. Royal Bank Of Canada reiterated an “outperform” rating and set a $205.00 target price on shares of Repligen in a research note on Tuesday, September 2nd. Jefferies Financial Group cut their target price on shares of Repligen from $145.00 to $135.00 and set a “hold” rating for the company in a research note on Friday, September 12th. Barclays began coverage on shares of Repligen in a research note on Tuesday, June 24th. They set an “overweight” rating and a $150.00 target price for the company. Finally, Wall Street Zen lowered shares of Repligen from a “buy” rating to a “hold” rating in a report on Sunday, June 29th. Nine equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $168.75.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.